MPS II (Hunter Syndrome) Disease Assessment

Evaluate clinical severity and treatment response in MPS II (Hunter syndrome, iduronate-2-sulfatase deficiency) across neurocognitive, skeletal, cardiac, and airway domains.

Weight
Height
Clinical Guidance

BMI is a screening measure of body size, not a direct measure of body fat. The standard WHO categories are underweight (<18.5), normal (18.5–24.9), overweight (25–29.9), and obese (≥30).

BMI can overestimate body fat in athletes with high muscle mass and underestimate it in older adults with low muscle mass. Interpret it alongside waist circumference and clinical context rather than as a standalone diagnosis.

⚕ Clinical Disclaimer: These calculators are for educational and reference purposes only. Always verify results with qualified clinical judgment and current clinical guidelines. Do not use as a sole basis for medical decisions.
Advertisement

How It Works

Evaluate clinical severity and treatment response in MPS II (Hunter syndrome, iduronate-2-sulfatase deficiency) across neurocognitive, skeletal, cardiac, and airway domains

Each component has a specific meaning:

  • Neurocognitive — The neurocognitive recorded for the scenario being assessed.
  • Skeletal — The skeletal recorded for the scenario being assessed.
  • Cardiac — The cardiac recorded for the scenario being assessed.
  • Airway domains — The airway domains recorded for the scenario being assessed.

Note: Interpret the mps ii score result against the thresholds and context described above.

How to Use

Enter the neurocognitive, skeletal, cardiac, airway domains for the scenario you are assessing. Evaluate clinical severity and treatment response in MPS II (Hunter syndrome, iduronate-2-sulfatase deficiency) across neurocognitive, skeletal, cardiac, and airway domains. Use the mps ii score result to inform your calculation.

Frequently Asked Questions